Dr. William (Wei) Cao, Ph.D. B.M., has been the Founder, Chairman and Chief Executive Office of Gracell Biotechnologies Group (Nasdaq: GRCL) since its foundation of May, 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry, including founded and co-founded two Nasdaq-listed companies in the field of cell & gene therapies. Prior to founding Gracell, Dr. Cao co-founded Cellular Biomedicine Group, Inc. (formerly Nasdaq: CBMG), a formerly Nasdaq-listed company engaged in the development of proprietary cell therapies for the treatment of cancer and degenerative diseases, and served as COO, CEO and director from August 2010 to January 2016. Before that, Dr. Cao served at senior scientific management positions at Chiron (Novartis and Bayer) and Affymetrix (ThermoFisher). Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College in Shanghai, China and a Ph.D. in Pharmacology from The Medical College of Virginia, U.S. Dr. Cao also has over 80 issued patents and applications for advanced cell therapies.